Industrial conglomerate 3M Company is partnering with the Massachusetts Institute of Technology to develop a cheaper, quicker COVID-19 test.
Right now, test results can take anywhere from a few hours to a week. Quest Diagnostics, for instance, said the average turnaround time at its labs is currently seven days.
3M's new test would function more like a pregnancy strip, a rapid paper-based test that could be mass-produced and quickly distributed at the point of care.
"In terms of patient experience, what we're looking to do is create that low-cost, highly-accurate, simple-to-use test that would be accessible to a lot of people," Dr. John Banovetz, chief technology officer for 3M, told Cheddar.
The antigen-based test, which looks at proteins on the virus, would offer a "preliminary view" of a patient's coronavirus status — though ideally, patients would follow up with a doctor, he added.
"Our goal would be a point-of-care test, so maybe it's taken in a doctor's office. Maybe you pick it up at the pharmacy," Banovetz said.
The goal is to start producing tests by the end of summer or early fall. Once manufacturing is rolling, 3M could produce millions of tests per day, according to the company.
As cases surge across the country and many anticipate a second wave in states where the infection rate has dropped off, calls for more testing are growing.
More than 41 million tests have been reported to the CDC, with a 9 percent positivity rate, but the U.S. continues to lag behind other countries by some measures.
In the meantime, the Trump administration is relying on the private sector to meet the demand for tests, putting pressure on companies such as 3M to come up with a solution.
"We're going as quick as we can right now," he said. "Our focus is trying to get that accuracy up and in a way that we know that we can mass-produce it. That's really where 3M can help contribute to this, our ability to be able to commercialize and bring to market new ideas and innovations."
Carlo and Baker cover the latest data showing the Omicron wave has likely started, Pfizer's Covid pill, Jan. 6 and a box office rescue attempt courtesy of Spider-Man.
Upward Farms is an indoor vertical farming company on a mission to heal our broken food system and reconnect consumers with organic locally-grown food. The Brooklyn-based company uses its controlled environment farms to grow organic leafy greens, which are sold at whole foods markets in New York City. Upward Farms co-founder and CEO Jason Green joined Cheddar Climate to discuss.
One of the biggest hurdles when it comes to widespread electric vehicle adoption is consumer hesitation about their ability to keep their EV charged if they take a longer trip outside of their locality. Now, electric companies nationwide are teaming up as part of a coalition to build out a network of EV charging stations spanning major U.S. travel corridors. Kellen Schefter, director of electric transportation at the Edison Electric Institute, joins Cheddar Climate to discuss the coalition's plans, how drivers can compare fueling up with gas to recharging an EV on a long trip, how the charging network will be funded, and more.
As more states begin to legalize recreational marijuana, there's a growing interest in legalizing cannabis cultivation. As the rise in cannabis farms expands across the U.S., more research is being done to examine its impact on the planet. Michael Katz, executive director at Mendocino Cannabis Alliance, joins Cheddar News to talk about the carbon footprint of cannabis farms.
Blue Origin launched its third manned mission over the weekend with 'Good Morning America' host Michael Strahan and Laura Shepard Churchley, daughter of astronaut Alan Shepard on board, alongside several Blue Origin investors.
This comes after the spaceflight firm launched two successful missions to the edge of space earlier this year. How will these missions set up Blue Origin for success as it competes with SpaceX and other companies for space tourism domination and more? Joey Roulette, space reporter at The New York Times, joins Cheddar News' Closing Bell to discuss.
Mina Makar, senior vice president of respiratory and immunology, Astrazeneca, joined Cheddar to discuss the FDA's decision to give emergency use authorization to the pharma giant's COVID-19 antibody treatment called Evusheld for immunocompromised patients For about 2 percent of the U.S. Makar noted that the injection is supposed to provide antibody protection for those who can't generate their own adequate immune response via the vaccines for a minimum of six months, though long-term trials are underway.
The pandemic has forced corporate America to reshape itself to adapt, including onboarding doctors as chief medical officers to help maintain the health and safety of staff. Dr. Geeta Nayyar, chief medical officer at Salesforce, joined Cheddar to break down her role and how it has become relevant and necessary in the evolving workplace. "Every business today is now in the business of healthcare," she said. "It is a priority to empower employees to then serve your customers."
Jonathan Adler, Law Professor at Case Western Reserve University, joined Wake Up With Cheddar to discuss Tuesday's ruling and provide legal context to recent battles over vaccine mandates.
Carlo and Baker wrap up the week talking about the Biden economic boom that no one seems to notice, a verdict in the Jussie Smollett case, the first Starbucks union in America and the pleasures of the "dude nod."
